XFOR Overview
Upcoming Projects (XFOR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (XFOR)
-
Discussing chronic neutropenia and the potential of Mavorixafor, a CXCR4 antagonist in development by X4 Pharmaceuticals
Ticker: XFOR
Executed On: Jun 20, 2023 at 12:30 PM EDT -
Evaluating the potential of new therapies in development for Waldenstrom macroglobulinemia with a focus on Iopofosine I 131 (CLR131) SM radiotherapeutic from Cellectar and mavorixafor from X4 Pharma
Tickers: CLRB, XFOR
Executed On: Sep 15, 2022 at 11:00 AM EDT
Expired Projects (XFOR)
-
Exploring Mavorixafor's Potential in Chronic Neutropenia: Insights from the Phase 2 Trial at ASH 2023
Ticker: XFOR
Execute By: Jan 31, 2024
Upcoming & Overdue Catalysts (XFOR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (XFOR)
-
X4 Pharmaceuticals (XFOR) presents new clinical data for Mavorixafor at ASH meeting
Ticker: XFOR
Occurred on: Dec 13, 2021
Strategic Initiatives (XFOR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
